Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:50873 |
Name | follicular lymphoma |
Definition | A B-cell lymphoma that is characterized as an indolent non-Hodgkin's lymphoma and has_material_basis_in follicle center B-cells (centrocytes and centroblasts). |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer lymphoma non-Hodgkin lymphoma B-cell lymphoma follicular lymphoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00577278 | Phase II | Ibritumomab tiuxetan Methotrexate + Sirolimus + Tacrolimus Rituximab Fludarabine + Melphalan | A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan | Completed | USA | 0 |
NCT00602693 | Phase I | Sirolimus Allopurinol + Cyclophosphamide + Fludarabine | T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer | Completed | USA | 0 |
NCT00671112 | Phase I | Bortezomib + Everolimus | Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma | Terminated | USA | 0 |
NCT01028716 | Phase II | Filgrastim + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Fludarabine | Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | Terminated | USA | 0 |
NCT01193842 | Phase Ib/II | Vorinostat Cyclophosphamide + Doxorubicin + Etoposide + Methylprednisolone + Rituximab + Vincristine Sulfate | Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas | Completed | USA | 0 |
NCT01216683 | Phase II | Bendamustine + Rituximab Bortezomib Lenalidomide | Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma | Completed | USA | 0 |
NCT01286272 | Phase II | Bendamustine + Ofatumumab Bendamustine + Bortezomib + Ofatumumab | Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT01307267 | Phase I | Rituximab + Utomilumab Utomilumab | A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab | Completed | USA | ITA | FRA | AUS | 1 |
NCT01473628 | Phase Ib/II | Rituximab | Radiation Therapy and Rituximab in Treating Patients With Stage I-II Grade 1 or Grade 2 Follicular Lymphoma | Recruiting | USA | 0 |
NCT01691898 | Phase Ib/II | Obinutuzumab + Pinatuzumab Vedotin + Rituximab Pinatuzumab Vedotin + Polatuzumab vedotin-piiq + Rituximab Obinutuzumab + Polatuzumab vedotin-piiq | A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (ROMULUS) | Completed | USA | NLD | ITA | FRA | DEU | CAN | 0 |
NCT01719250 | Phase I | Buparlisib | Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | Completed | USA | 0 |
NCT01732913 | Phase III | Idelalisib Rituximab | Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas | Terminated | USA | SWE | ROU | POL | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CZE | AUS | 6 |
NCT01732926 | Phase III | Idelalisib Bendamustine + Rituximab | Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas | Terminated | USA | SWE | POL | ITA | ISR | GBR | FRA | ESP | DEU | CZE | CAN | AUS | 3 |
NCT01796171 | Phase Ib/II | Lilotomab Betalutin Rituximab | A Phase I/II Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-01) | Completed | USA | TUR | SWE | POL | NOR | NLD | ITA | ISR | IRL | HUN | HRV | GBR | FRA | FIN | ESP | DNK | CZE | CHE | CAN | BEL | AUT | AUS | 2 |
NCT01804686 | Phase III | Ibrutinib | A Long-term Extension Study of PCI-32765 (Ibrutinib) | Enrolling by invitation | USA | TUR | SWE | POL | NLD | ITA | ISR | IRL | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUS | ARG | 10 |
NCT01811368 | Phase II | anti-thymocyte globulin + Ibritumomab tiuxetan + Rituximab Cyclosporine + Mycophenolate mofetil | Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma | Unknown status | USA | 0 |
NCT01897012 | Phase I | Romidepsin Alisertib | Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas | Completed | USA | 0 |
NCT01953692 | Phase I | Pembrolizumab | A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013)(KEYNOTE-013) | Completed | 0 | |
NCT01955499 | Phase I | Ibrutinib + Lenalidomide | Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | Active, not recruiting | USA | CAN | 0 |
NCT01974440 | Phase III | Ibrutinib Bendamustine + Rituximab Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Sulfate | A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma | Completed | USA | TUR | SWE | POL | ISR | GBR | FRA | ESP | DEU | BRA | BEL | AUS | ARG | 6 |
NCT01976585 | Phase Ib/II | CDX-301 + Poly ICLC | In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy | Completed | USA | 0 |
NCT01994382 | Phase I | Cerdulatinib | Phase 1 Dose Escalation Study in Chronic Lymphocytic Leukemia and Non-hodgkin Lymphoma | Completed | USA | 0 |
NCT02038946 | Phase II | Nivolumab | Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140) | Completed | USA | SWE | NOR | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 1 |
NCT02049541 | Phase I | Buparlisib + Rituximab | Study of BKM120; Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma | Completed | USA | 0 |
NCT02082977 | Phase I | GSK126 | A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell and Transformed Follicular Lymphoma | Terminated | USA | GBR | FRA | 0 |
NCT02106091 | Phase I | AFM11 | Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL | Terminated | USA | POL | DEU | CZE | 0 |
NCT02187861 | Phase II | Bendamustine + Rituximab Bendamustine + Rituximab + Venetoclax Rituximab + Venetoclax | A Study Evaluating the Safety and Efficacy of GDC-0199 (ABT-199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or GDC-0199 Plus Rituximab in Patients With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma | Completed | USA | ITA | GBR | FRA | DEU | CAN | BEL | AUS | 0 |
NCT02194751 | Phase II | Oncoquest-L vaccine | Oncoquest-L Vaccine in Patients With Previously Untreated Stage III or IV, Asymptomatic, Non-bulky Follicular Lymphoma | Not yet recruiting | USA | 0 |
NCT02208037 | Phase II | Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) | Completed | USA | 0 | |
NCT02220842 | Phase I | Atezolizumab + Obinutuzumab | A Safety and Pharmacology Study of MPDL3280A Administered With Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma | Completed | USA | ITA | GBR | FRA | DEU | 0 |
NCT02254772 | Phase Ib/II | Ipilimumab + SD-101 | TLR9 Agonist SD-101, Ipilimumab, and Radiation Therapy in Treating Patients With Low-Grade Recurrent B-cell Lymphoma | Completed | USA | 0 |
NCT02257567 | Phase Ib/II | Bendamustine + Rituximab Polatuzumab vedotin-piiq Obinutuzumab | A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma | Completed | USA | TUR | NLD | ITA | HUN | GBR | FRA | ESP | DEU | CZE | CAN | AUS | 1 |
NCT02266147 | Phase Ib/II | SD-101 | Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma | Terminated | USA | 0 |
NCT02282358 | Phase Ib/II | Mocetinostat | Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | Terminated | USA | 0 |
NCT02320292 | Phase III | Rituximab Ibritumomab tiuxetan + Rituximab | Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma | Completed | USA | 0 |
NCT02339922 | Phase II | Ixazomib + Rituximab | Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT02343536 | Phase I | Cyclophosphamide + Prednisone + Rituximab + Vincristine Sulfate Azacitidine | A Phase 1, Open-label,Trial of Oral Azacitidine (CC-486) Plus R-CHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma | Completed | USA | 0 |
NCT02348216 | Phase Ib/II | axicabtagene ciloleucel | A Phase 1-2 Multi-Center Study Evaluating KTE-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1) | Completed | USA | NLD | ISR | FRA | DEU | CAN | 0 |
NCT02367040 | Phase III | Rituximab Copanlisib | Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) | Active, not recruiting | USA | TUR | SVK | ROU | POL | NZL | LTU | ITA | IRL | HUN | GRC | FRA | ESP | DEU | BRA | BGR | BEL | AUT | AUS | ARG | 17 |
NCT02369016 | Phase III | Copanlisib | Phase III Copanlisib in Rituximab-refractory iNHL | Completed | TUR | POL | ITA | GRC | BRA | BGR | 4 |
NCT02376699 | Phase I | Pembrolizumab + SEA-CD40 SEA-CD40 | Safety Study of SEA-CD40 in Cancer Patients | Terminated | USA | 0 |
NCT02381080 | Phase I | Erythromycin + Ibrutinib + Voriconazole | Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy | Completed | ESP | CAN | 1 |
NCT02384954 | Phase Ib/II | Nogapendekin alfa inbakicept + Rituximab | ALT-803 in Patients With Relapse/Refractory Indolent B Cell Non-Hodgkin Lymphoma (iNHL) in Conjunction With Rituximab | Terminated | USA | 0 |
NCT02393157 | Phase II | Carboplatin + Etoposide + Ifosfamide + Obinutuzumab Cytarabine | Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL (O-ICE) | Recruiting | USA | 0 |
NCT02401048 | Phase Ib/II | Durvalumab + Ibrutinib | A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas | Completed | USA | 0 |
NCT02440685 | Phase Ib/II | ASN002 | A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors | Terminated | USA | ARG | 0 |
NCT02446457 | Phase II | Pembrolizumab + Rituximab | Study of Rituximab Plus Pembrolizumab (MK-3475) in Subjects With Relapsed Follicular Lymphoma | Active, not recruiting | USA | 0 |
NCT02454270 | Phase II | JNJ-64052781 | A Dose Escalation Study of JNJ-64052781 in Participants With Relapsed or Refractory B-cell Malignancies | Terminated | USA | ISR | FRA | ESP | BEL | 0 |
NCT02457598 | Phase I | Entospletinib + Tirabrutinib Tirabrutinib Idelalisib + Obinutuzumab + Tirabrutinib Entospletinib + Obinutuzumab + Tirabrutinib Idelalisib + Tirabrutinib | Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies | Terminated | USA | GBR | FRA | 0 |
NCT02471911 | Phase I | Dexamethasone Carboplatin + Etoposide + Ifosfamide + Rituximab Selinexor | KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma | Completed | USA | 0 |
NCT02501473 | Phase Ib/II | GLA-SE + Pembrolizumab | Study of Intratumoral G100 Therapy in Patients With Or Without Pembrolizumab With Follicular Non-Hodgkin's Lymphoma | Terminated | 0 | |
NCT02532192 | Phase I | Rituximab Cisplatin Dexamethasone Cytarabine Fluconazole Belinostat | A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma | Withdrawn | 0 | |
NCT02532257 | Phase II | Ibrutinib + Lenalidomide + Rituximab | Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma | Completed | USA | 0 |
NCT02536300 | Phase III | Idelalisib | Dose Optimization Study of Idelalisib in Follicular Lymphoma | Terminated | ROU | POL | ITA | ISR | GBR | FRA | ESP | CZE | CAN | AUS | 0 |
NCT02564744 | Phase II | Naratuximab emtansine + Rituximab | Study to Evaluate the Efficacy and Tolerability Debio 1562 in Combination With Rituximab in Patients With Relapsed and/or Refractory DLBCL and Other Forms of NHL | Completed | USA | POL | ITA | HUN | CZE | CHE | BGR | BEL | 1 |
NCT02576275 | Phase III | Bendamustine + Rituximab Duvelisib | A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) | Withdrawn | USA | 0 |
NCT02596971 | Phase Ib/II | Atezolizumab + Bendamustine + Obinutuzumab Atezolizumab + Cyclophosphamide + Doxorubicin + Obinutuzumab + Prednisone + Vincristine Sulfate Atezolizumab + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate | A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) | Completed | USA | ITA | AUS | 0 |
NCT02600897 | Phase Ib/II | Lenalidomide + Rituximab Lenalidomide + Obinutuzumab Lenalidomide + Polatuzumab vedotin-piiq + Rituximab Lenalidomide + Obinutuzumab + Polatuzumab vedotin-piiq | A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Completed | USA | GBR | ESP | 0 |
NCT02603445 | Phase I | BCL201 + Idelalisib | Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL | Completed | USA | FRA | DEU | AUT | 0 |
NCT02605694 | Phase II | Duvelisib + Rituximab Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate | Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO) | Withdrawn | USA | 0 |
NCT02611323 | Phase Ib/II | Polatuzumab vedotin-piiq + Rituximab + Venetoclax Obinutuzumab + Polatuzumab vedotin-piiq + Venetoclax | A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) | Completed | USA | ITA | AUS | 0 |
NCT02624986 | Phase Ib/II | Idasanutlin + Obinutuzumab | A Study of Obinutuzumab With Idasanutlin in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) | Terminated | USA | NZL | DEU | AUS | 1 |
NCT02626455 | Phase III | Vincristine Sulfate Prednisone Aldoxorubicin + Cyclophosphamide + Prednisone + Rituximab + Vincristine Sulfate Copanlisib Bendamustine + Rituximab Rituximab | Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) (CHRONOS-4) | Terminated | USA | TUR | SVK | ROU | POL | ITA | ISR | IRL | HUN | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BRA | BGR | BEL | AUS | 13 |
NCT02631044 | Phase I | Lisocabtagene maraleucel | Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) | Completed | USA | 0 |
NCT02631577 | Phase I | Atezolizumab + Lenalidomide + Obinutuzumab | A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma | Completed | USA | FRA | 0 |
NCT02650999 | Phase Ib/II | Pembrolizumab | Study of Pembrolizumab in Patients Failing to Respond to or Relapsing After Anti-CD19 Chimeric Antigen Receptor Modified T Cell Therapy for Relapsed or Refractory CD19+ Lymphomas | Completed | USA | 0 |
NCT02700022 | Phase I | Alisertib Cyclophosphamide + Doxorubicin + Etoposide + Methylprednisolone + Rituximab + Vincristine Sulfate | A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas | Terminated | USA | 0 |
NCT02722668 | Phase II | Cyclophosphamide + Fludarabine + Mycophenolate mofetil Sirolimus anti-thymocyte globulin | UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep | Active, not recruiting | USA | 0 |
NCT02729896 | Phase Ib/II | Obinutuzumab + Polatuzumab vedotin-piiq + Rituximab Atezolizumab + Obinutuzumab + Polatuzumab vedotin-piiq | A Study of Obinutuzumab, Polatuzumab Vedotin, and Atezolizumab in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) | Completed | USA | POL | DEU | 0 |
NCT02743546 | Phase I | Ibrutinib + JNJ-64052781 | Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of JNJ-64052781 Plus Ibrutinib in Lymphoma | Withdrawn | 0 | |
NCT02747043 | Phase III | ABP 798 Rituximab | Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab (JASMINE) | Completed | USA | ROU | POL | ITA | ISR | GRC | FRA | ESP | DEU | CZE | CAN | BGR | AUS | 7 |
NCT02756247 | Phase I | Buparlisib + Ibrutinib | A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma | Completed | USA | 0 |
NCT02776813 | Phase I | ACTR087 + Rituximab | Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma | Completed | USA | 0 |
NCT02797470 | Phase Ib/II | Carmustine + CCR5 shRNA/TRIM5a/TAR decoy-transduced CD34+ HPCs + Cytarabine + Etoposide + Melphalan | Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant | Active, not recruiting | USA | 0 |
NCT02869633 | Phase II | Ibrutinib | Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant | Completed | USA | 0 |
NCT02875223 | Phase I | CC-90011 | A Safety and Efficacy Study of CC-90011 in Subjects With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas | Terminated | ITA | GBR | FRA | ESP | 1 |
NCT02889523 | Phase Ib/II | Cyclophosphamide + Doxorubicin + Prednisolone + Rituximab + Tazemetostat + Vincristine Sulfate | Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy (Epi-RCHOP) | Active, not recruiting | FRA | BEL | 0 |
NCT02900716 | Phase I | DTRMWXHS-12 + Everolimus + Pomalidomide DTRMWXHS-12 DTRMWXHS-12 + Everolimus | Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas | Completed | USA | 0 |
NCT02914938 | Phase I | zandelisib Rituximab + zandelisib | A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma | Terminated | USA | CHE | 0 |
NCT02927964 | Phase Ib/II | Ibrutinib + Radiotherapy + SD-101 | TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma | Completed | USA | 0 |
NCT02931110 | Phase I | CBL0137 | Study of IV CBL0137 in Previously Treated Hematological Subjects | Terminated | USA | 0 |
NCT02947347 | Phase III | Ibrutinib Ibrutinib + Rituximab | Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma | Active, not recruiting | USA | TUR | POL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | ESP | CZE | CAN | BEL | AUT | AUS | 3 |
NCT02950220 | Phase I | Ibrutinib + Pembrolizumab | Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | Completed | USA | 0 |
NCT02953509 | Phase Ib/II | Hu5F9-G4 + Rituximab | Trial of Hu5F9-G4 in Combination With Rituximab in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma | Terminated | USA | GBR | AUS | 0 |
NCT02956382 | Phase Ib/II | Ibrutinib + Venetoclax | Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma | Active, not recruiting | USA | 0 |
NCT02966730 | Phase I | Ibrutinib | Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy | Terminated | USA | 0 |
NCT02992522 | Phase I | Lenalidomide + Obinutuzumab + Venetoclax | Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT03010358 | Phase Ib/II | Entospletinib + Obinutuzumab | Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma | Completed | USA | 0 |
NCT03015896 | Phase Ib/II | Lenalidomide + Nivolumab | Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT03019640 | Phase II | Carmustine + Cytarabine + Etoposide + Filgrastim + Lenalidomide + Melphalan + Rituximab | Immunotherapy With Ex Vivo-Expanded Cord Blood-Derived NK Cells Combined With Rituximab High-Dose Chemotherapy and Autologous Stem Cell Transplant for B-Cell Non-Hodgkin's Lymphoma | Completed | USA | 0 |
NCT03039114 | Phase I | Bendamustine + Obinutuzumab + Parsaclisib | Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102) | Completed | USA | ITA | HUN | ESP | DNK | CZE | 0 |
NCT03085173 | Phase I | EGFRt/19-28z/4-1BBL CAR T cells | A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies | Active, not recruiting | USA | 0 |
NCT03105336 | Phase II | axicabtagene ciloleucel | A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5) | Active, not recruiting | USA | FRA | 0 |
NCT03113422 | Phase II | Obinutuzumab Obinutuzumab + Venetoclax Bendamustine + Obinutuzumab + Venetoclax | Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy (PrE0403) | Completed | USA | 0 |
NCT03121677 | Phase I | Nivolumab + Poly ICLC + Rituximab | Personalized Synthetic Long Peptide Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma | Terminated | USA | 0 |
NCT03126019 | Phase II | Parsaclisib Idelalisib | An Open-Label, Randomized Study Comparing INCB050465 to Idelalisib in Relapsed or Refractory Follicular Lymphoma (CITADEL-203) | Completed | USA | SWE | POL | ITA | ISR | HUN | GBR | ESP | DNK | DEU | CZE | CAN | AUS | 0 |
NCT03129828 | Phase Ib/II | Bortezomib + Cyclophosphamide + Doxorubicin + Ibrutinib + Prednisone + Rituximab + Vincristine Sulfate | Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI >= 2 (ImbruVeRCHOP) | Active, not recruiting | DEU | 0 |
NCT03133221 | Phase II | Idelalisib | 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation | Active, not recruiting | USA | 0 |
NCT03135262 | Phase Ib/II | Idasanutlin + Rituximab + Venetoclax Idasanutlin + Obinutuzumab + Venetoclax Idasanutlin + Obinutuzumab + Rituximab + Venetoclax | A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL) | Terminated | USA | NZL | DEU | AUS | 1 |
NCT03147885 | Phase Ib/II | Selinexor | Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT03150329 | Phase I | Pembrolizumab + Vorinostat | Pembrolizumab and Vorinostat in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, or Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT03153462 | Expanded access | axicabtagene ciloleucel + Cyclophosphamide + Fludarabine | Axicabtagene Ciloleucel Expanded Access Study | Approved for marketing | USA | 0 |
NCT03156114 | Phase I | Ezabenlimab Miptenalimab | This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment. | Completed | USA | POL | GBR | ESP | CAN | 0 |
NCT03178201 | Phase II | Umbralisib | TGR1202 in Relapsed and Refractory Follicular Lymphoma | Terminated | USA | 0 |
NCT03179930 | Phase II | Entinostat + Pembrolizumab | Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas | Active, not recruiting | USA | 0 |
NCT03189836 | Phase I | ACTR707 + Rituximab | Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma | Terminated | USA | 0 |
NCT03198026 | Phase II | Ibrutinib + Obinutuzumab | Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas | Recruiting | USA | 0 |
NCT03220347 | Phase I | CC-90010 | A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas | Terminated | ITA | FRA | ESP | 1 |
NCT03245021 | Phase I | Nivolumab + Rituximab Nivolumab | Nivolumab Plus Rituximab in First-line Follicular Lymphoma gr 1-3A (1stFLOR) | Active, not recruiting | AUS | 0 |
NCT03269669 | Phase II | Cyclophosphamide + Doxorubicin + Obinutuzumab + Prednisone + Vincristine Sulfate Lenalidomide + Obinutuzumab Obinutuzumab + Umbralisib Prednisone | Obinutuzumab With or Without PI3K-delta Inhibitor TGR-1202, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma | Active, not recruiting | USA | 0 |
NCT03277729 | Phase Ib/II | CD20 CAR-T cells + Cyclophosphamide + Fludarabine | A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas | Active, not recruiting | USA | 0 |
NCT03297424 | Phase Ib/II | PLX2853 | A Study of PLX2853 in Advanced Malignancies. | Completed | USA | 0 |
NCT03321643 | Phase I | Atezolizumab + Gemcitabine + Oxaliplatin + Rituximab Atezolizumab + Rituximab | Atezolizumab, Gemcitabine, Oxaliplatin, and Rituximab in Treating Patients With Relapsed or Refractory Transformed Diffuse Large B-Cell Lymphoma | Active, not recruiting | USA | 0 |
NCT03332017 | Phase II | Obinutuzumab + Zanubrutinib Obinutuzumab | A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma | Active, not recruiting | USA | POL | NZL | ITA | GBR | FRA | ESP | DEU | CZE | CAN | BGR | AUS | 5 |
NCT03341520 | Phase II | Obinutuzumab | Gazyvaro and Low Dose Radiotherapy in Early Stage Follicular Lymphoma (GAZAI) | Active, not recruiting | DEU | 0 |
NCT03357627 | Phase I | Mivavotinib + Venetoclax | A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma | Completed | USA | DEU | CAN | 0 |
NCT03361852 | Phase I | NeoVax + Rituximab | A Pilot Study of a Personalized Neoantigen Cancer Vaccine Following Front-Line Rituximab in Follicular Lymphoma | Active, not recruiting | USA | 0 |
NCT03379493 | Phase I | Study of ET190L1-ARTEMIS T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma | Terminated | USA | 0 | |
NCT03401853 | Phase II | Pembrolizumab + Rituximab | Rituximab and Pembrolizumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma | Active, not recruiting | USA | 0 |
NCT03422679 | Phase Ib/II | CB-103 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies | Terminated | USA | FRA | ESP | DEU | CHE | 1 |
NCT03424122 | Phase I | Ibrutinib + Parsaclisib Bendamustine + Parsaclisib + Rituximab Parsaclisib + Rituximab | INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112) | Completed | USA | ITA | ESP | 0 |
NCT03424603 | Phase I | STRO-001 | Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies | Completed | USA | 0 |
NCT03460977 | Phase I | PF-06821497 | PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma | Recruiting | USA | POL | ESP | BGR | 4 |
NCT03465891 | Phase II | Atezolizumab | Study of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular Lymphoma | Terminated | USA | 0 |
NCT03479268 | Phase I | Ibrutinib + MLN4924 | Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT03483103 | Phase II | Lisocabtagene maraleucel | Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006) | Completed | USA | 0 |
NCT03484702 | Phase II | Lisocabtagene maraleucel | Trial to Determine the Efficacy and Safety of JCAR017 in Adult Subjects With Aggressive B-Cell Non-Hodgkin Lymphoma (TRANSCENDWORLD) | Completed | NLD | ITA | GBR | FRA | FIN | ESP | DEU | CHE | BEL | AUT | 1 |
NCT03498612 | Phase II | Pembrolizumab | Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases | Active, not recruiting | USA | 0 |
NCT03533283 | Phase I | Glofitamab-gxbm + Obinutuzumab Glofitamab-gxbm + Obinutuzumab + Polatuzumab vedotin-piiq + Tocilizumab Atezolizumab + Glofitamab-gxbm + Obinutuzumab + Tocilizumab | An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | Active, not recruiting | USA | ITA | ISR | GBR | ESP | DNK | BEL | 0 |
NCT03547115 | Phase I | Voruciclib | A Phase 1 Study of Voruciclib in Subjects With B-Cell Malignancies | Recruiting | USA | 0 |
NCT03568461 | Phase II | Tisagenlecleucel | Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma (ELARA) | Active, not recruiting | USA | NOR | NLD | ITA | GBR | FRA | ESP | DEU | BEL | AUT | AUS | 1 |
NCT03571568 | Phase Ib/II | BI-1206 + Rituximab | A Study of BI-1206 in Combination With Rituximab in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma | Recruiting | USA | SWE | POL | ESP | DEU | BRA | 0 |
NCT03571828 | Phase I | AMG562 | Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma | Terminated | USA | DEU | CAN | BEL | 0 |
NCT03579927 | Phase Ib/II | Filgrastim iC9-CAR.19-IL15-Transduced CB-NK Carmustine + Cytarabine + Etoposide + Melphalan + Rituximab | CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma | Withdrawn | USA | 0 |
NCT03585725 | Phase I | Ribavirin | A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma | Terminated | USA | 0 |
NCT03600441 | Phase II | Abexinostat | Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma (FORERUNNER) | Active, not recruiting | USA | FRA | ESP | 0 |
NCT03610724 | Phase II | Tisagenlecleucel | Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients (BIANCA) | Completed | USA | NOR | NLD | ITA | GBR | FRA | FIN | ESP | DNK | DEU | CAN | AUT | AUS | 1 |
NCT03625037 | Phase Ib/II | Epcoritamab-bysp | First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma (EPCORE™ NHL-1) | Active, not recruiting | USA | SWE | POL | NLD | ITA | GBR | FRA | FIN | ESP | DNK | DEU | CAN | AUS | 2 |
NCT03636503 | Phase I | Avelumab + Rituximab + Utomilumab Avelumab + PF-04518600 + Rituximab PF-04518600 + Rituximab + Utomilumab | RITUXIMAB + IMMUNOTHERAPY IN FOLLICULAR LYMPHOMA | Unknown status | USA | 0 |
NCT03671018 | Phase I | Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Prednisone + Rituximab + Vincristine Sulfate Bendamustine + Polatuzumab vedotin-piiq + Rituximab Bendamustine + Obinutuzumab Mosunetuzumab-axgb + Polatuzumab vedotin-piiq Mosunetuzumab-axgb Obinutuzumab Tocilizumab | A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma | Active, not recruiting | USA | GBR | ESP | CAN | BEL | 0 |
NCT03682796 | Phase I | TRPH-222 | Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma | Completed | USA | CAN | 0 |
NCT03685344 | Phase I | Durvalumab + Loncastuximab tesirine-lpyl | Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma | Terminated | USA | ESP | 0 |
NCT03696784 | Phase I | Rimiducid Bendamustine + Fludarabine + iC9-CAR.19-IL15-Transduced CB-NK | Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma | Recruiting | USA | 0 |
NCT03711578 | Phase II | Tenalisib | Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K delta/gamma Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL) | Completed | USA | AUS | 0 |
NCT03740529 | Phase Ib/II | Cyclophosphamide + Doxorubicin + Pirtobrutinib + Prednisone + Rituximab + Vincristine Sulfate Pirtobrutinib + Rituximab + Venetoclax Pirtobrutinib + Venetoclax Pirtobrutinib | A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL | Active, not recruiting | USA | SWE | POL | ITA | GBR | FRA | CHE | AUS | 2 |
NCT03744676 | Phase II | Lisocabtagene maraleucel | A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) | Completed | USA | 0 |
NCT03755154 | Phase I | VOB560 | Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia | Terminated | GBR | FRA | ESP | AUS | 0 |
NCT03758989 | Phase II | Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate | A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma | Recruiting | USA | 0 |
NCT03765177 | Phase Ib/II | CLIC-1901 | CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies (CLIC-01) | Recruiting | CAN | 0 |
NCT03768505 | Phase II | zandelisib | Study of ME-401 in Subjects With Follicular Lymphoma After Failure of Two or More Prior Systemic Therapies | Terminated | USA | POL | NZL | ITA | GBR | FRA | ESP | DEU | CHE | BEL | AUT | AUS | 2 |
NCT03779113 | Phase Ib/II | HMPL-523 | An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma | Active, not recruiting | USA | POL | ITA | FRA | FIN | ESP | DNK | 0 |
NCT03786926 | Phase Ib/II | HMPL-689 | Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas | Active, not recruiting | USA | POL | ITA | FRA | FIN | ESP | 0 |
NCT03789240 | Phase II | Copanlisib + Rituximab | Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma | Active, not recruiting | USA | 0 |
NCT03828448 | Phase II | Ublituximab + Umbralisib | Study to Assess Umbralisib Plus Ublituximab in Patients With Treatment Naive Follicular Lymphoma | Terminated | USA | 0 |
NCT03833180 | Phase I | VLS-101 | A Phase 1 Dose-Escalation and Cohort-Expansion of VLS-101 in Hematologic Malignancies | Completed | USA | 0 |
NCT03884998 | Phase I | Copanlisib + Nivolumab | Copanlisib and Nivolumab in Treating Participants With Richter's Transformation or Transformed Indolent Non-Hodgkin's Lymphoma | Active, not recruiting | USA | 0 |
NCT03888105 | Phase II | Odronextamab | Assess the Anti-Tumor Activity and Safety of REGN1979 in Patients With Relapsed or Refractory Follicular Lymphoma | Recruiting | USA | POL | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 5 |
NCT03892044 | Phase I | Duvelisib + Nivolumab | Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma | Completed | USA | 0 |
NCT03919175 | Phase II | Rituximab + Umbralisib | Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma | Terminated | USA | 0 |
NCT03920631 | Phase I | Nivolumab | Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas (MicroBLITZ) | Withdrawn | USA | 0 |
NCT03939026 | Phase I | UCART19 ALLO-647 + Cyclophosphamide + Fludarabine | Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma (ALPHA) | Active, not recruiting | USA | 0 |
NCT03976102 | Phase III | Rituximab DRL_RI | Compare the Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular Lymphoma (FLINTER) | Completed | USA | 0 |
NCT03980171 | Phase Ib/II | Lenalidomide + Obinutuzumab + Venetoclax | Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Naïve Follicular Lymphoma (LEVERAGE) | Active, not recruiting | AUS | 0 |
NCT04007029 | Phase I | Tocilizumab Anti-CD19-CD20 CAR T cells + Cyclophosphamide + Fludarabine | Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia | Recruiting | USA | 0 |
NCT04014205 | Phase I | Orelabrutinib | A Study of Tyrosine Kinase Inhibitor ICP-022 in Patients With r/r B-Cell Malignancies | Active, not recruiting | USA | POL | ISR | 1 |
NCT04038359 | Phase II | Duvelisib | A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Subjects With Indolent Non-Hodgkin Lymphoma. (TEMPO) | Completed | USA | POL | ITA | GBR | DEU | CZE | 2 |
NCT04072458 | Phase I | BP1002 | A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies | Recruiting | USA | 0 |
NCT04074330 | Phase Ib/II | Rituximab + Subasumstat | A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma | Terminated | USA | ITA | GBR | FRA | ESP | DEU | CAN | 2 |
NCT04082936 | Phase I | IGM-2323 | A Safety and Pharmacokinetic Study of IGM-2323 in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma | Terminated | USA | ITA | FRA | ESP | CZE | AUS | 1 |
NCT04136275 | Phase I | Anti-CD37 CAR T cells | CAR-37 T Cells In Hematologic Malignancies | Completed | USA | 0 |
NCT04156828 | Phase I | Carboplatin + Copanlisib + Dexamethasone + Gemcitabine + Pegfilgrastim + Rituximab | Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma | Terminated | USA | 0 |
NCT04161118 | Phase II | huCART19 | TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma (TIGER-CTL019) | Terminated | DEU | 0 |
NCT04205409 | Phase II | Nivolumab | Nivolumab for the Treatment of Relapsed or Refractory Hematologic Malignancies | Active, not recruiting | USA | 0 |
NCT04223765 | Phase I | Bendamustine + CAR.k.28 cells + Fludarabine CAR.k.28 cells + Cyclophosphamide + Fludarabine | Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT04224493 | Phase III | Lenalidomide + Rituximab + Tazemetostat Lenalidomide + Rituximab | Study in Subjects With Relapsed/Refractory Follicular Lymphoma | Recruiting | USA | POL | ITA | HUN | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 3 |
NCT04231747 | Phase I | CC-97540 | A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | Completed | USA | CAN | 0 |
NCT04243499 | Phase I | ICT01 | First-in-Human Study of ICT01 in Patients With Advanced Cancer (EVICTION) | Recruiting | USA | GBR | FRA | ESP | DEU | BEL | 0 |
NCT04245839 | Phase II | Lisocabtagene maraleucel Cyclophosphamide + Fludarabine | A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) (TRANSCEND FL) | Recruiting | USA | SWE | ITA | GBR | FRA | ESP | DEU | CAN | AUT | 1 |
NCT04246086 | Phase Ib/II | Tocilizumab Lenalidomide + Mosunetuzumab-axgb | A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma | Recruiting | USA | GBR | FRA | ESP | 1 |
NCT04263584 | Phase II | Copanlisib + Cyclophosphamide + Doxorubicin + Prednisolone + Rituximab + Vincristine Sulfate | Copanlisib in Combination With Rituximab and CHOP Chemotherapy in Patients With Previously Untreated DLBCL (COPA-R-CHOP) | Active, not recruiting | DEU | 0 |
NCT04277637 | Phase I | BGB-11417 + Zanubrutinib BGB-11417 | Study of Bcl-2 Inhibitor BGB-11417 in Participants With Mature B-Cell Malignancies | Recruiting | USA | NZL | ITA | GBR | ESP | DEU | AUS | 0 |
NCT04282018 | Phase Ib/II | BGB-10188 + Zanubrutinib BGB-10188 + Tislelizumab BGB-10188 | Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab | Completed | AUS | 1 |
NCT04283097 | Phase I | KPG-818 | Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects | Recruiting | USA | 0 |
NCT04390737 | Phase I | HH2853 | A Phase I Study to Evaluate the Safety and Clinical Activity of HH2853. | Recruiting | USA | 1 |
NCT04401020 | Phase I | SAR442257 | First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL | Active, not recruiting | USA | NOR | ESP | CZE | 1 |
NCT04404088 | Phase II | Acalabrutinib + Lenalidomide + Rituximab | Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma | Active, not recruiting | USA | 0 |
NCT04419909 | Phase I | huCART19 | Retreatment With CTL019/CTL119 | Not yet recruiting | USA | 0 |
NCT04431635 | Phase I | Copanlisib + Nivolumab + Rituximab | Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma | Terminated | USA | 0 |
NCT04447716 | Phase I | Lenalidomide + Rituximab Hyaluronidase + Venetoclax Lenalidomide + Rituximab + Venetoclax | An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment | Recruiting | USA | 0 |
NCT04450173 | Phase II | Ibrutinib + Obinutuzumab + Venetoclax | Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma | Recruiting | USA | 0 |
NCT04464798 | Phase I | Iberdomide Iberdomide + Obinutuzumab Iberdomide + Rituximab | A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas | Active, not recruiting | USA | ITA | FRA | DEU | 2 |
NCT04491370 | Phase Ib/II | Polatuzumab vedotin-piiq | Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT04502706 | Phase I | FSI-189 FSI-189 + Rituximab | Study of FSI-189 as Monotherapy and in Combination With Rituximab in Participants With Relapsed/Refractory Non-Hodgkin Lymphoma | Terminated | USA | 0 |
NCT04508647 | Phase II | Ublituximab Ublituximab + Umbralisib | Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma | Completed | USA | 0 |
NCT04531046 | Phase II | axicabtagene ciloleucel | Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation | Active, not recruiting | FRA | BEL | 0 |
NCT04540796 | Phase I | JNJ-75348780 | A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) | Active, not recruiting | USA | ISR | GBR | FRA | ESP | AUS | 2 |
NCT04545762 | Phase I | Anti-CD19 CAR-T cells Cyclophosphamide + Fludarabine | Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT04569032 | Phase II | Brentuximab vedotin + Cyclophosphamide + Doxorubicin + Prednisone | A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression | Active, not recruiting | USA | ITA | GBR | FRA | ESP | CZE | 0 |
NCT04578600 | Phase I | Azacitidine + Lenalidomide + Obinutuzumab | CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma | Active, not recruiting | USA | 0 |
NCT04587687 | Phase II | Bendamustine + Brentuximab vedotin | Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma | Recruiting | USA | 0 |
NCT04594642 | Phase I | TNB-486 | A Study of TNB-486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | Recruiting | USA | AUS | 3 |
NCT04594798 | Phase II | Cyclophosphamide + Doxorubicin + Polatuzumab vedotin-piiq + Prednisone + Rituximab | A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL | Recruiting | USA | 0 |
NCT04599634 | Phase I | Hu5F9-G4 + Obinutuzumab + Venetoclax | Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies | Completed | USA | 0 |
NCT04628494 | Phase III | Gemcitabine + Oxaliplatin + Rituximab Epcoritamab-bysp Bendamustine + Rituximab | A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in R/R DLBCL (EPCORE DLBCL-1) | Active, not recruiting | USA | TUR | SWE | POL | NOR | NLD | ITA | ISR | HUN | GBR | FRA | FIN | ESP | DNK | DEU | CAN | BEL | AUT | AUS | 6 |
NCT04635683 | Phase I | Lenalidomide + Ublituximab + Umbralisib | Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma | Withdrawn | 0 | |
NCT04659044 | Phase II | Polatuzumab vedotin-piiq + Rituximab + Rituximab Hyaluronidase + Venetoclax Rituximab Hyaluronidase + Venetoclax | Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma | Terminated | USA | 0 |
NCT04663347 | Phase Ib/II | Epcoritamab-bysp Cisplatin + Cytarabine + Dexamethasone + Epcoritamab-bysp + Rituximab Epcoritamab-bysp + Gemcitabine + Oxaliplatin Epcoritamab-bysp + Lenalidomide + Rituximab Bendamustine + Epcoritamab-bysp + Rituximab Cyclophosphamide + Doxorubicin + Epcoritamab-bysp + Prednisone + Rituximab + Vincristine Sulfate Epcoritamab-bysp + Lenalidomide | Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) (EPCORE™ NHL-2) | Recruiting | USA | SWE | NOR | NLD | ITA | GBR | FRA | FIN | ESP | DNK | CZE | BEL | AUS | 0 |
NCT04669171 | Phase Ib/II | EO2463 EO2463 + Lenalidomide + Rituximab EO2463 + Rituximab | A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma (SIDNEY) | Recruiting | USA | ITA | ESP | 0 |
NCT04680052 | Phase III | Lenalidomide + Rituximab Lenalidomide + Rituximab + Tafasitamab-cxix | A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. (InMIND) | Active, not recruiting | USA | TUR | SWE | POL | NOR | NLD | ITA | ISR | IRL | HUN | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CHE | CAN | BEL | AUT | AUS | 5 |
NCT04699461 | Phase II | Idelalisib Loncastuximab tesirine-lpyl | Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma (LOTIS 6) | Terminated | USA | POL | ITA | ISR | HUN | GBR | FRA | ESP | CHE | BEL | 0 |
NCT04712097 | Phase III | Lenalidomide + Mosunetuzumab-axgb + Tocilizumab Lenalidomide + Rituximab + Tocilizumab | A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma (Celestimo) | Recruiting | USA | TUR | POL | ITA | GBR | FRA | ESP | DEU | BRA | AUS | 6 |
NCT04722601 | Phase Ib/II | Azacitidine + Venetoclax Azacitidine + Obinutuzumab + Venetoclax Obinutuzumab | A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma | Terminated | USA | 0 |
NCT04728893 | Phase II | ARQ 531 | Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) | Recruiting | USA | TUR | ROU | POL | ITA | ISR | IRL | HUN | GBR | FRA | ESP | DNK | DEU | CZE | CHE | CAN | BRA | AUS | ARG | 3 |
NCT04745832 | Phase III | Rituximab + zandelisib Bendamustine + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate | Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL) | Terminated | USA | TUR | POL | NZL | NLD | ITA | HUN | GRC | GBR | FRA | ESP | CAN | BEL | AUS | 5 |
NCT04750941 | Phase II | Copanlisib | Study of Copanlisib and Ketogenic Diet | Active, not recruiting | USA | 0 |
NCT04762160 | Phase II | Rituximab + Tazemetostat | SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma | Terminated | USA | 0 |
NCT04775745 | Phase I | LP-168 | Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. | Recruiting | USA | 0 |
NCT04792502 | Phase II | Lenalidomide + Mosunetuzumab-axgb | Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma | Recruiting | USA | 0 |
NCT04799275 | Phase II | Azacitidine + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate | Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma | Recruiting | USA | 0 |
NCT04809467 | Phase Ib/II | Parsaclisib + Tafasitamab-cxix | A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) (topMIND) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | BEL | AUT | 0 |
NCT04824092 | Phase III | Cyclophosphamide + Doxorubicin + Lenalidomide + Prednisone + Rituximab + Tafasitamab-cxix + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate | Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients (frontMIND) | Active, not recruiting | USA | TUR | SVK | ROU | POL | NZL | ITA | ISR | IRL | HUN | GBR | FRA | ESP | DEU | CZE | CAN | AUT | AUS | ARG | 10 |
NCT04830137 | Phase I | NX-2127 | A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies | Recruiting | USA | 0 |
NCT04836195 | Phase I | PCLX-001 | Phase I Trial of PCLX-001 in R/R Advanced Solid Malignancies and B-cell Lymphoma | Recruiting | CAN | 0 |
NCT04836832 | Phase I | Acalabrutinib + Duvelisib | Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma | Withdrawn | 0 | |
NCT04842877 | Phase II | DS-3201b | Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma | Active, not recruiting | FRA | BEL | 0 |
NCT04844866 | Phase II | Bendamustine + Polatuzumab vedotin-piiq + Rituximab Gemcitabine + Oxaliplatin + Rituximab Zamtocabtagene autoleucel | Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients (DALY 2-EU) | Active, not recruiting | SWE | POL | NLD | LTU | ITA | HUN | FRA | ESP | DEU | CZE | BEL | AUT | 0 |
NCT04853329 | Phase Ib/II | CPO107 | Dose Escalation and Expansion Study of CPO107 for Patients With Advanced CD20-positive Non-Hodgkins Lymphoma | Suspended | USA | 0 |
NCT04861779 | Phase I | HSK29116 | A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies | Unknown status | AUS | 1 |
NCT04882163 | Phase Ib/II | Cisplatin + Dexamethasone + Gemcitabine + Iberdomide + Rituximab Lenalidomide + Tafasitamab-cxix Iberdomide + Polatuzumab vedotin-piiq + Rituximab Iberdomide + Tafasitamab-cxix Bendamustine + Polatuzumab vedotin-piiq + Rituximab | Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma | Withdrawn | USA | GBR | FRA | ESP | BEL | AUT | 2 |
NCT04883437 | Phase II | Acalabrutinib + Obinutuzumab | Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas | Recruiting | USA | 0 |
NCT04889716 | Phase II | Glofitamab-gxbm + Obinutuzumab Mosunetuzumab-axgb | CAR-T Followed by Bispecific Antibodies | Recruiting | USA | 0 |
NCT04903197 | Phase I | Lenalidomide + VAY736 VAY736 | Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma | Active, not recruiting | ITA | DEU | AUS | 4 |
NCT04934930 | Phase II | Bendamustine + Obinutuzumab | Adjustment of Chemotherapy Duration in Follicular Lymphoma According to Minimal Residual Disease Status (FLMRD) | Recruiting | ISR | 0 |
NCT04962126 | Phase II | Atezolizumab + Obinutuzumab | Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy (FLUORO) | Active, not recruiting | AUS | 0 |
NCT04974216 | Phase II | Lenalidomide + Rituximab + Tafasitamab-cxix | Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older | Active, not recruiting | FRA | BEL | 0 |
NCT04975555 | Phase II | Siltuximab | Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy | Recruiting | USA | 0 |
NCT04980222 | Phase II | Cyclophosphamide + Doxorubicin + Glofitamab-gxbm + Prednisone + Rituximab + Vincristine Sulfate | A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma | Active, not recruiting | USA | POL | NLD | FRA | ESP | DNK | 0 |
NCT04998669 | Phase II | Loncastuximab tesirine-lpyl + Rituximab | Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma | Recruiting | USA | 0 |
NCT05003141 | Phase I | PSB202 | PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies | Unknown status | USA | AUS | 1 |
NCT05005442 | Phase II | MK-7684A | A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004) | Active, not recruiting | USA | TUR | POL | ITA | ISR | HUN | FRA | ESP | DNK | DEU | CAN | BRA | 4 |
NCT05006716 | Phase I | BGB-16673 | A Phase 1 Dose-Escalation and Expansion Study of BGB-16673 in Patients With B-Cell Malignancies | Recruiting | USA | TUR | SWE | ITA | GBR | FRA | ESP | DEU | CAN | BRA | AUS | 3 |
NCT05008055 | Phase II | Capivasertib | Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL) | Active, not recruiting | USA | GBR | FRA | ESP | DNK | CAN | 1 |
NCT05010005 | Phase I | Duvelisib + Ruxolitinib | A Study of Ruxolitinib and Duvelisib in People With Lymphoma | Active, not recruiting | USA | 0 |
NCT05020015 | Phase II | iC9-CAR.19-IL15-Transduced CB-NK Cyclophosphamide + Fludarabine | A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) | Active, not recruiting | USA | 0 |
NCT05025800 | Phase Ib/II | Evorpacept + Lenalidomide + Rituximab | ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT05077527 | Phase I | axicabtagene ciloleucel Cyclophosphamide + Fludarabine | Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT05100862 | Phase III | Rituximab + Zanubrutinib Lenalidomide + Rituximab Obinutuzumab + Zanubrutinib | A Study of Zanubrutinib Versus Lenalidomide in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma (MAHOGANY) | Recruiting | USA | TUR | ROU | POL | ITA | ISR | IRL | GRC | GBR | FRA | ESP | CZE | CHE | CAN | BRA | BGR | BEL | AUT | AUS | ARG | 4 |
NCT05131022 | Phase I | NX-5948 | Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies | Recruiting | USA | NLD | GBR | 0 |
NCT05152459 | Phase Ib/II | Tazemetostat + Ublituximab + Umbralisib | Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma | Withdrawn | 0 | |
NCT05169515 | Phase I | Glofitamab-gxbm + Iberdomide CC-99282 + Glofitamab-gxbm CC-99282 + Mosunetuzumab-axgb Iberdomide + Mosunetuzumab-axgb | A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma | Recruiting | USA | ITA | ISR | GBR | ESP | 0 |
NCT05169658 | Phase II | Mosunetuzumab-axgb + Obinutuzumab + Polatuzumab vedotin-piiq | Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT05171647 | Phase III | Mosunetuzumab-axgb + Polatuzumab vedotin-piiq Mosunetuzumab-axgb + Polatuzumab vedotin-piiq + Tocilizumab Gemcitabine + Oxaliplatin + Rituximab | A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (SUNMO) | Active, not recruiting | USA | TUR | NZL | ISR | CAN | BRA | ARG | 6 |
NCT05205161 | Phase Ib/II | AZD0466 | A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma | Terminated | USA | ITA | FRA | ESP | AUS | 2 |
NCT05205252 | Phase Ib/II | Lenalidomide + Tafasitamab-cxix + Tazemetostat Daratumumab + Dexamethasone + Pomalidomide + Tazemetostat Daratumumab and hyaluronidase-fihj + Dexamethasone + Pomalidomide + Tazemetostat Mosunetuzumab-axgb + Tazemetostat Lenalidomide + Tazemetostat Acalabrutinib + Tazemetostat | A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer. (ARIA) | Withdrawn | USA | 0 |
NCT05207670 | Phase II | Mosunetuzumab-axgb + Tocilizumab | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | Active, not recruiting | USA | 0 |
NCT05211336 | Phase I | Lenalidomide + Nivolumab Ibrutinib + Lenalidomide + Obinutuzumab + Prednisone + Venetoclax | Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid With Nivolumab (VIPOR-Nivo) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System | Active, not recruiting | USA | 0 |
NCT05256641 | Phase Ib/II | Acalabrutinib | Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma | Recruiting | USA | 0 |
NCT05260957 | Phase II | Mosunetuzumab-axgb + Polatuzumab vedotin-piiq | CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL). | Recruiting | USA | 0 |
NCT05275504 | Phase I | TT-01488 | Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies | Unknown status | USA | 0 |
NCT05283720 | Phase II | Epcoritamab-bysp + Lenalidomide Epcoritamab-bysp + Ibrutinib + Lenalidomide Cyclophosphamide + Doxorubicin + Epcoritamab-bysp + Polatuzumab vedotin-piiq + Prednisone + Rituximab | A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma | Recruiting | USA | NLD | ISR | HUN | FRA | ESP | DNK | DEU | CZE | 3 |
NCT05296525 | Phase Ib/II | GDA-201 | Evaluation of Safety and Efficacy of Allo GDA-201 NK Cells in Patients With Relapsed/Refractory B Cell NHL | Terminated | USA | 0 |
NCT05315713 | Phase Ib/II | Mosunetuzumab-axgb + Tiragolumab + Tocilizumab Atezolizumab + Mosunetuzumab-axgb + Tiragolumab + Tocilizumab | An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma | Terminated | USA | GBR | DEU | CAN | BEL | AUS | 0 |
NCT05336409 | Phase I | CNTY-101 | A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies (ELiPSE-1) | Recruiting | USA | 0 |
NCT05338346 | Phase I | ATG-018 | A Study of ATG-018 (ATR Inhibitor) Treatment in Patients With Advanced Solid Tumors and Hematological Malignancies (ATRIUM) | Terminated | AUS | 0 |
NCT05348889 | Phase Ib/II | 1A46 | First-in-Human (FIH) Trial of 1A46 in Subjects With Advanced CD20 and/or CD19 Positive B-cell Hematologic Malignancies | Recruiting | USA | 0 |
NCT05359211 | Phase I | NKTR-255 Cyclophosphamide + Fludarabine + Lisocabtagene maraleucel | NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma | Recruiting | USA | 0 |
NCT05360238 | Phase Ib/II | MB-106 | Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL | Terminated | USA | 0 |
NCT05365659 | Phase I | IKS03 | IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas | Recruiting | USA | ITA | ESP | CAN | AUS | 0 |
NCT05371093 | Phase III | axicabtagene ciloleucel Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Fludarabine Bendamustine + Rituximab Lenalidomide + Rituximab | Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma (ZUMA-22) | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | 1 |
NCT05387616 | Phase II | Copanlisib + Obinutuzumab | A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination With Obinutuzumab in Patients With Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden (Alternative-C) | Active, not recruiting | DEU | 0 |
NCT05389293 | Phase II | Mosunetuzumab-axgb | A Study of Mosunetuzumab in People With Follicular Lymphoma | Recruiting | USA | 0 |
NCT05409066 | Phase III | Lenalidomide + Rituximab Epcoritamab-bysp + Lenalidomide + Rituximab | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | Recruiting | USA | TUR | SWE | SVK | POL | NZL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 6 |
NCT05410418 | Phase II | Mosunetuzumab-axgb + Polatuzumab vedotin-piiq | Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma | Recruiting | USA | 0 |
NCT05412290 | Phase I | Mosunetuzumab-axgb | Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma | Recruiting | USA | 0 |
NCT05421663 | Phase I | C-CAR039 | A Study of JNJ-90014496 in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | Recruiting | USA | NLD | GBR | ESP | DNK | CAN | AUS | 1 |
NCT05429268 | Phase III | Lenalidomide + Tafasitamab-cxix | Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND) | Recruiting | TUR | ROU | POL | NOR | ISR | IRL | HUN | HRV | GBR | FIN | DNK | CZE | BGR | 1 |
NCT05451810 | Phase II | Epcoritamab-bysp | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma | Recruiting | USA | 1 |
NCT05453396 | Phase II | Loncastuximab tesirine-lpyl | Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies | Recruiting | USA | 0 |
NCT05455697 | Phase Ib/II | Cyclophosphamide + Doxorubicin + Prednisone + Retifanlimab + Rituximab + Tafasitamab-cxix + Vincristine Sulfate | Tafasitamab, Retifanlimab, and Rituximab in Combination With Chemotherapy (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) for the Treatment of Diffuse Large B-cell Lymphoma | Recruiting | USA | 0 |
NCT05458297 | Phase II | VLS-101 ARQ 531 + VLS-101 | A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination With Nemtabrutinib (MK-1026) in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) | Recruiting | USA | TUR | SWE | POL | ITA | ISR | IRL | GBR | EST | ESP | DEU | CZE | CAN | BRA | 7 |
NCT05459571 | Phase II | axicabtagene ciloleucel + Cyclophosphamide + Dexamethasone + Fludarabine | Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma (ZUMA-24) | Active, not recruiting | USA | 0 |
NCT05464329 | Phase I | Mosunetuzumab-axgb | Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Autologous Stem Cell Transplant-Eligible Patients With Relapsed/Refractory Aggressive B Cell Lymphoma | Recruiting | USA | 0 |
NCT05507541 | Phase II | Pembrolizumab + TTI-622 Pembrolizumab + TTI-621 | TTI-622 and TTI-621 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Recruiting | USA | 0 |
NCT05512390 | Phase I | ABBV-319 | A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL) | Recruiting | USA | ISR | CAN | AUS | 0 |
NCT05551936 | Phase Ib/II | Bendamustine + Rituximab + Tazemetostat | A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma | Recruiting | USA | 0 |
NCT05588440 | Phase Ib/II | Cyclophosphamide + Fludarabine ONCT-808 | A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies | Terminated | USA | 0 |
NCT05602363 | Phase I | AS-1763 | AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT05604417 | Phase Ib/II | Tazemetostat + zandelisib | Zandelisib + Tazemetostat in R/R Follicular Lymphoma | Withdrawn | 0 | |
NCT05607420 | Phase Ib/II | Alemtuzumab UCART20X22 | Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma (NatHaLi-01) | Recruiting | USA | FRA | ESP | 0 |
NCT05615636 | Phase II | Lenalidomide + Mosunetuzumab-axgb + Polatuzumab vedotin-piiq + Tafasitamab-cxix | A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL | Recruiting | USA | 0 |
NCT05618366 | Phase I | Tazemetostat + Venetoclax | Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT05633615 | Phase II | Cyclophosphamide + Fludarabine axicabtagene ciloleucel + Lisocabtagene maraleucel + Tisagenlecleucel Polatuzumab vedotin-piiq Mosunetuzumab-axgb Mosunetuzumab-axgb + Polatuzumab vedotin-piiq | Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | Recruiting | USA | 0 |
NCT05641428 | Phase II | axicabtagene ciloleucel ARI-0001 | Comparison of Point-of-care Produced CAR T-cell With Commercial CAR T-cells in Patients With R/R LBCL (HOVON161) | Recruiting | NLD | 0 |
NCT05664217 | Phase II | NKTR-255 | NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma | Recruiting | USA | 0 |
NCT05672251 | Phase II | Loncastuximab tesirine-lpyl + Mosunetuzumab-axgb | Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Recruiting | USA | 0 |
NCT05683171 | Phase Ib/II | DS-3201b + Lenalidomide + Rituximab | A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma | Recruiting | USA | 0 |
NCT05702853 | Phase Ib/II | CD19-CD34 CAR transduced T cells Cyclophosphamide + Fludarabine | Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL | Recruiting | USA | 0 |
NCT05737628 | Phase I | BYON4228 + Rituximab | First-in-human Dose Escalation and Expansion Study With the SIRPalpha-directed Monoclonal Antibody BYON4228 | Recruiting | NLD | ITA | GBR | ESP | 0 |
NCT05753501 | Phase I | ABBV-101 | Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies | Recruiting | USA | ISR | GBR | FRA | ESP | DEU | CAN | 1 |
NCT05773040 | Phase I | JV-213 | A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas | Active, not recruiting | USA | 0 |
NCT05780034 | Phase I | AC0676 | A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies | Recruiting | USA | 0 |
NCT05783596 | Phase II | Glofitamab-gxbm + Obinutuzumab | Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma | Recruiting | USA | 0 |
NCT05783609 | Phase II | Epcoritamab-bysp + Rituximab | Epcoritamab and Rituximab for First-line Follicular Lymphoma | Recruiting | USA | 0 |
NCT05784441 | Phase I | JNJ-90009530 | A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL) | Recruiting | USA | ISR | GBR | AUS | 0 |
NCT05788081 | Phase II | CC-99282 + Nivolumab + Rituximab CC-99282 + Rituximab | Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab. (TOP-FLOR) | Recruiting | AUS | 0 |
NCT05797233 | Phase I | Cyclophosphamide + Fludarabine Anti-CD19-CD20 CAR T cells | Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies | Active, not recruiting | USA | 0 |
NCT05798897 | Phase I | MT-601 | Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma (APOLLO) | Recruiting | USA | 0 |
NCT05820841 | Phase III | Cyclophosphamide + Doxorubicin + Prednisolone + Rituximab + Vincristine Sulfate Acalabrutinib + Cyclophosphamide + Doxorubicin + Prednisolone + Rituximab + Vincristine Sulfate | Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma (ARCHED) | Recruiting | DEU | 0 |
NCT05821088 | Phase II | Carboplatin + Etoposide + Ifosfamide + Lenalidomide + Tafasitamab-cxix | Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma | Recruiting | USA | 0 |
NCT05828589 | Phase I | BGB-21447 | A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies | Recruiting | AUS | 1 |
NCT05848765 | Phase II | Bendamustine + Obinutuzumab Epcoritamab-bysp + Lenalidomide Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Bendamustine + Rituximab Cyclophosphamide + Prednisone + Rituximab + Vincristine Sulfate Lenalidomide + Rituximab | Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy (REFRACT) | Recruiting | GBR | 0 |
NCT05852717 | Phase II | Cisplatin + Dexamethasone + Epcoritamab-bysp + Gemcitabine | Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma | Recruiting | USA | 0 |
NCT05878184 | Phase I | Cyclophosphamide + Fludarabine SC291 | Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT) | Active, not recruiting | USA | AUS | 0 |
NCT05879744 | Phase I | CLN-978 | A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL) | Active, not recruiting | USA | 0 |
NCT05888493 | Phase III | Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Tisagenlecleucel Cyclophosphamide + Doxorubicin + Prednisolone + Rituximab + Vincristine Sulfate Lenalidomide + Rituximab | A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma (LEDA) | Recruiting | SVK | ROU | POL | HUN | ESP | CZE | AUS | 3 |
NCT05890352 | Phase II | Lenalidomide + Tafasitamab-cxix Lenalidomide + Tafasitamab-cxix + Tazemetostat Lenalidomide + Tafasitamab-cxix + Zanubrutinib | Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment | Recruiting | USA | 0 |
NCT05929716 | Phase II | Hu5F9-G4 + Rituximab | An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma | Withdrawn | 0 | |
NCT05934838 | Phase I | Tazemetostat | A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas | Recruiting | USA | 0 |
NCT05950165 | Phase Ib/II | CHO-H01 + Lenalidomide CHO-H01 | A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma | Recruiting | USA | 1 |
NCT05950334 | Phase I | Bendamustine + FT522 + Rituximab Cyclophosphamide + Fludarabine + FT522 + Rituximab FT522 + Rituximab | FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101) | Recruiting | USA | 0 |
NCT05967416 | Phase I | SIRPant-M | Phase 1, Open-Label Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma | Recruiting | USA | 0 |
NCT05989204 | Phase I | HuCART19-IL18 | TmCD19-IL18 in CD19+ Cancers | Recruiting | USA | 0 |
NCT05994235 | Phase II | Mosunetuzumab-axgb + Tazemetostat | Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma | Recruiting | USA | 0 |
NCT06014762 | Phase I | P-CD19CD20-ALLO1 | P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies | Recruiting | USA | 0 |
NCT06026319 | Phase I | CD79b-19 CAR T cells Cyclophosphamide + Fludarabine | CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT06043323 | Phase II | axicabtagene ciloleucel Cyclophosphamide + Fludarabine | A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma | Recruiting | USA | 0 |
NCT06071871 | Phase II | Glofitamab-gxbm + Obinutuzumab + Polatuzumab vedotin-piiq | A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab as a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma (PORTAL) | Recruiting | GBR | 0 |
NCT06088654 | Phase Ib/II | IPH6501 | Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma | Recruiting | USA | FRA | AUS | 0 |
NCT06090539 | Phase I | BMS-986458 + Rituximab BMS-986458 | A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas | Recruiting | USA | NLD | FRA | ESP | DEU | CHE | 0 |
NCT06091254 | Phase III | Odronextamab Cyclophosphamide + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Bendamustine + Rituximab | A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Participants With Follicular Lymphoma (OLYMPIA-1) | Recruiting | USA | TUR | POL | ITA | ISR | GBR | FRA | ESP | DEU | CZE | CHE | CAN | AUT | AUS | 2 |
NCT06097364 | Phase III | Rituximab Cyclophosphamide + Doxorubicin + Odronextamab + Prednisone + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Odronextamab Cyclophosphamide + Odronextamab + Prednisone + Vincristine Sulfate | A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma (OLYMPIA-2) | Recruiting | USA | TUR | POL | ITA | ISR | GBR | ESP | BEL | AUS | 3 |
NCT06101381 | Phase Ib/II | huCART19 | CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma (CARTHEDRALL) | Not yet recruiting | BRA | 0 |
NCT06108232 | Phase II | CC-99282 + Obinutuzumab | Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma | Recruiting | USA | 0 |
NCT06112847 | Phase II | Epcoritamab-bysp + Lenalidomide | Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma | Recruiting | USA | 0 |
NCT06149286 | Phase III | Lenalidomide + Rituximab Lenalidomide + Odronextamab | A Trial to Learn if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Participants With Follicular Lymphoma and Marginal Zone Lymphoma (OLYMPIA-5) | Recruiting | USA | TUR | POL | ITA | ISR | GBR | FRA | ESP | DEU | CZE | BEL | AUT | AUS | 4 |
NCT06191744 | Phase III | Epcoritamab-bysp + Lenalidomide + Rituximab Bendamustine + Obinutuzumab Lenalidomide + Rituximab Cyclophosphamide + Doxorubicin + Obinutuzumab + Prednisone + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Bendamustine + Rituximab | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCORE™FL-2) | Recruiting | USA | TUR | SWE | SVK | ROU | POL | NZL | NLD | ITA | ISR | HUN | HRV | GRC | GBR | FRA | ESP | DNK | DEU | CZE | BGR | BEL | AUS | 8 |
NCT06191887 | Phase I | Bendamustine BAFFR-CAR T cells Cyclophosphamide + Fludarabine | B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies | Recruiting | USA | 0 |
NCT06209619 | Phase I | CC-99282 + Rituximab | CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma | Recruiting | USA | 0 |
NCT06248086 | Phase I | ASP101G + ASP2802 | A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas | Recruiting | AUS | 0 |
NCT06256484 | Phase I | ATA3219 | A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT06284122 | Phase III | Bendamustine + Obinutuzumab Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Bendamustine + Rituximab Lenalidomide + Mosunetuzumab-axgb Cyclophosphamide + Doxorubicin + Obinutuzumab + Prednisone + Vincristine Sulfate | Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5 (MorningLyte) | Recruiting | FRA | ESP | DEU | BEL | 1 |
NCT06285422 | Phase I | Cyclophosphamide + Fludarabine SC262 | Study Evaluating SC262 in Subjects With r/r B-cell Malignancies (VIVID) | Recruiting | USA | 0 |
NCT06287398 | Phase II | Epcoritamab-bysp Cytarabine + Dexamethasone + Epcoritamab-bysp + Oxaliplatin + Rituximab | Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL | Recruiting | AUS | 0 |
NCT06290622 | Phase I | INCAGN02385 + INCAGN02390 + Retifanlimab | PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL | Withdrawn | USA | 0 |
NCT06337318 | Phase III | Mosunetuzumab-axgb Rituximab Hyaluronidase + Rituximab | Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma | Recruiting | USA | 0 |
NCT06340737 | Phase I | Anti-CD22 CAR T cells | AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas | Recruiting | USA | 0 |
NCT06343376 | Phase I | EGFRt/19-28z/IL-12 CAR-T cells Cyclophosphamide + Fludarabine | Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies | Recruiting | USA | 0 |
NCT06350318 | Phase II | Rituximab + Zanubrutinib | Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas | Recruiting | USA | 0 |
NCT06378190 | Phase Ib/II | TranspoCART19 | Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology (TranspoCART19) | Recruiting | ESP | 0 |
NCT06392477 | Phase I | DR-0201 | A Study of DR-0201 in Subjects With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma | Recruiting | AUS | 5 |
NCT06425302 | Phase II | Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Bendamustine + Rituximab CC-99282 + Rituximab | A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma (GOLSEEK-2) | Recruiting | USA | POL | ITA | GBR | FRA | ESP | DEU | CAN | BRA | AUS | 3 |
NCT06442475 | Phase II | Mosunetuzumab-axgb | Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma | Recruiting | USA | 0 |
NCT06453044 | Phase II | Mosunetuzumab-axgb + Polatuzumab vedotin-piiq | Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma | Recruiting | USA | 0 |
NCT06484920 | Phase II | Pembrolizumab + Tretinoin | A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL | Recruiting | USA | 0 |
NCT06486051 | Phase II | Cyclophosphamide + Fludarabine WZTL-002 | A Study of WZTL-002 CAR T-cells for Adults With Relapsed Large B-cell Lymphoma (ENABLE-2) | Recruiting | NZL | 0 |
NCT06492304 | Phase Ib/II | CTX131 | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies | Recruiting | USA | 0 |
NCT06492837 | Phase II | Mosunetuzumab-axgb + Zanubrutinib | Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients (FIL_MOZART) | Not yet recruiting | ITA | 0 |
NCT06510361 | Phase II | Epcoritamab-bysp | A Phase 2 Study of Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a Complete Response With Upfront Chemoimmunotherapy | Not yet recruiting | USA | 0 |
NCT06526793 | Phase II | TNB-486 | AZD0486 as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL | Not yet recruiting | USA | ESP | DEU | CAN | BRA | AUS | 2 |
NCT06536049 | Phase Ib/II | Epcoritamab-bysp + Ibrutinib | Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma | Not yet recruiting | USA | 0 |
NCT06542250 | Phase Ib/II | AZD5492 | A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies. (TITANium) | Recruiting | USA | ITA | FRA | ESP | DNK | DEU | CAN | AUS | 1 |
NCT06549595 | Phase III | Rituximab + TNB-486 Cyclophosphamide + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Bendamustine + Rituximab | A Study of AZD0486 Plus Rituximab in Previously Untreated Follicular Lymphoma Patients | Recruiting | TUR | SWE | POL | GBR | FIN | ESP | CAN | BEL | AUS | 5 |
NCT06561425 | Phase Ib/II | GLPG5101 | A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma (Atalanta-1) | Recruiting | USA | NLD | BEL | 0 |
NCT06563596 | Phase II | Epcoritamab-bysp + Rituximab + Zanubrutinib | Epcoritamab, Zanubrutinib, and Rituximab (EZR) for R/R FL Relapsed or Refractory Follicular Lymphoma | Not yet recruiting | USA | 0 |
NCT06575686 | Phase II | Tazemetostat Epcoritamab-bysp + Tazemetostat | Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma | Not yet recruiting | USA | 0 |